In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A

Biomaterials

Volumn 32, Issue 16, 2011, Pages 4052-4057

  Sarti, Federica ^a   Perera, Glen ^a   Hintzen, Fabian ^a   Kotti, Katerina ^b   Karageorgiou, Vassilis ^b   Kammona, Olga ^b   Kiparissides, Costas ^b   Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Centre for Research and Technology Hellas   (Greece)

Author keywords

Immune response; Mucosa; Oral delivery; Ovalbumin; Poly(dl lactide co glycolide) nanoparticles; Vaccination

Indexed keywords

IMMUNE RESPONSE; MUCOSA; ORAL DELIVERY; OVALBUMIN; POLY(DL-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES; VACCINATION;

IMMUNOLOGY; ORGANIC POLYMERS; POLYMERS;

NANOPARTICLES;

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NANOPARTICLE; OVALBUMIN; PHOSPHORYL LIPID A; POLYGLACTIN; RESOMER;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; LYMPHOID TISSUE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; LACTIC ACID; LIPID A; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; OVALBUMIN; POLYGLYCOLIC ACID; VACCINATION;

MUS;

EID: 79953025756     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.02.011     Document Type: Article

References (41)

1. Kakutani H., Kondoh M., Fukasaka M., Suzuki H., Hamakubo T. Mucosal vaccination using claudin-4-targeting. Biomaterials 2010, 31:5463-5471.
2. Ryan E.J., Daly L.M., Mills K.H. Immunomodulators and delivery systems for vaccinations by mucosal routes. Trends Biotechnol 2001, 19:293-304.
3. van der Lubben I.M., Verhoef J.C., van Aelst A.C., Borchard G., Junginger H.E. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001, 22:687-694.
4. Shalaby W.S.W. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. Clin Immunol Immunopath 1995, 74:127-134.
5. des Rieux A., Fievez V., Garinot M., Schneider Y.J., Preat V. Nanoparticles as potential oral delivery systems for proteins and vaccines: a mechanistic approach. J Control Release 2006, 116:1-27.
6. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996, 189:503-505.
7. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 2008, 125:193-209.
8. Igartua M., Hernandez R.M., Esquisabel A., Gascon A.R., Calvo M.B., Pedraz J.L. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release 1998, 56:63-73.
9. Chong C.S.W., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticles vaccine delivery. J Control Release 2005, 102:85-99.
10. Waeckerle-Men Y., Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005, 57:475-482.
11. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589:1-13.
12. Hamdy S., Haddadi A., Somayaji V., Ruan D., Samuel J. Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly(d,l-lactic-co-glycolic acid) nanoparticle formulations. J Pharm Biomed Anal 2007, 44:914-923.
13. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007, 6:133-140.
14. Hamdy S., Elamanchili P., Alshamsan A., Molavi O., Satou T., Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-lke receptor ligand monophosphoryl lipid A in poly(d,l-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 2007, 81:652-662.
15. Baldridge J.R., Yorgensen Y., Ward J.R., Ulrich T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000, 18:2416-2425.
16. McNeela E.A., Mills K.H.G. Manipulating the immune system: humoral versus cell mediated immunity. Adv Drug Del Rev 2001, 51:43-54.
17. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D.T. Encapsulation of the immune potentiators MPL and RC529 in PLGA microparticles enhances their potency. J Control Release 2006, 110:566-573.
18. Moore A., McCarthy L., Mills K.H.G. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 and Th1. Vaccine 1999, 17:2517-2527.
19. Sasaki S., Tsuji T., Hamajima K., Fukushima J., Ishii N., Kaneko T., et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune response to DNA vaccination against human immunodeficiency virus type 1. Infect Immun 1997, 65:3520-3528.
20. Elamanchili P., Lutsiak C.M., Hamdy S., Diwan S., Samuel J. " Pathogenic mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunotherapy 2007, 30:378-395.
21. Elamanchili P., Diwan M., Cao M., Samuel J. Characterization of poly(d,l-lactic-co -glycolic acid) based nanoparticulate systems for enhanced delivery of antigens to dendritic cells. Vaccine 2004, 22:2406-2412.
22. Elson C.O., Ealding W., Lefkowitz J. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J Immunol Methods 1986, 67:101-108.
23. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligands in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.
24. Zhao A., Rodgers V.G.J. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles. J Control Release 2006, 113:15-22.
25. O'Hagan D.T., Jeffery H., Davis S.S. The preparation and characterization of poly(lactide-co-glycolide) microparticles: III. Microparticle/polymer degradation rates and the in vitro release of a model protein. Int J Pharm 1994, 103:37-45.
26. Desai M.P., Labhasetwar V., Walter E., Levy R.J., Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is ize dependent. Pharm Res 1997, 14:1568-1573.
27. Qaddoumi M.G., Ueda H., Yang J., Davda J., Labhasetwar V., Lee V.H.L. The characteristic and mechanism of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layer. Pharm Res 2004, 21:641-648.
28. Rentel C.O., Bouwstra J.A., Naisbett B., Junginger H.E. Niosomes as a novel peroral vaccine delivery system. Int J Pharm 1999, 186:161-167.
29. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11:S63-S68.
30. Matzelle M.M., Babensee J.E. Humoral immune responses to model antigen codelivered with biomaterials used in tissue engineering. Biomaterials 2004, 25:295-304.
31. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991, 73:239-242.
32. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Verhoef J.C., Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 2003, 21:1400-1408.
33. Shi L., Caulfield M.J., Chern R.T., Wilson R.A., Sanyal G., Volkin D.B. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 2002, 91:1019-1035.
34. Kavanagh O.V., Earley B., Murray M., Foster C.J., Adair B.M. Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(dl-lactide-co-glycolide) microspheres. Vaccine 2003, 21:4472-4480.
35. Bivas-Benita M., Lin M.Y., Bal S.M., van Meijgaarden K., Franken K.L.M.C., Friggen A.H., et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 2009, 27:4010-4017.
36. O'Hagan D.T., Jeffery H., Davis S.S. Long-term antibody responses following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11:965-969.
37. Warren H.S., Chedid L.A. Future prospects for vaccine adjuvants. Crit Rev Immunol 1988, 8:83-101.
38. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995, 6:495-524.
39. Baldrich J.R., Richardson D., Elliot G., Wheeler A.W. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol 2002, 35:398-413.
40. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine in press.
41. Lutsiak M.E.C., Kwon G.S., Samuel J. Biodegradable nanoparticles delivery of a Th2 biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006, 58:739-747.